A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

Exclusion Criteria

• •1. Diagnosis of PH in World Health Organization (WHO) Group 1, WHO Group 3, WHO Group 4, or WHO Group 5.
• •2. Historical or current evidence of a clinically significant disease or disorder.
• •3. Decompensated HF or hospitalisation due to decompensated HF.
• •4. Any contraindications to RHC.
• •5. History of hypersensitivity to SC injections or devices.
• •6. History of hypersensitivity to drugs with a similar chemical structure or class to AZD3427 or any component of AZD3427 drug product, or ongoing clinically important allergy/hypersensitivity.
• •7. Known lung disease with Forced expiratory volume in the first second (FEV1) \< 30% of predicted.
• •8. Congenital long QT syndrome.
• •9. Cardiac ventricular arrhythmia which requires treatment. Participants with atrial fibrillation or flutter and controlled ventricular rate are permitted.
• •10. History of or anticipated heart transplant or ventricular assist device implantation.
• •11. Any known planned (scheduled) highly invasive Cardiovascular (CV) procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter, valve repair/replacement, aortic aneurysm surgery, etc).
• •12. Participants who have previously received AZD3427.